Raffles Medical    Last:0.93    -0.015

Raffles Medical

haha, good balance shit hor.. lols
well, market always react to such news, somehow the sentiment no good
looking at TA chart, bearish pin spotted today
and its below ema 200 for TF daily chart
 

halleluyah      ( Date: 24-Feb-2022 13:10) Posted: 6mth qoq profit just drop 7.2% a bit niah but yoy profit up so much 29.5%.......yeah cash rich, rev up...gd balance shit.... ridethestorm      ( Date: 24-Feb-2022 12:26) Posted: cash rich and revenue up....the price is downtrend...

 

6mth qoq profit just drop 7.2% a bit niah but yoy profit up so much 29.5%.......yeah cash rich, rev up...gd balance shit....

ridethestorm      ( Date: 24-Feb-2022 12:26) Posted: cash rich and revenue up....the price is downtrend...   halleluyah      ( Date: 24-Feb-2022 08:53) Posted: flw coy buy....attractive to long.....wat a jokes wth 3 hosp yet the px is still like donkey yrs ago...

 

cash rich and revenue up....the price is downtrend...
 

halleluyah      ( Date: 24-Feb-2022 08:53) Posted: flw coy buy....attractive to long.....wat a jokes wth 3 hosp yet the px is still like donkey yrs ago.... halleluyah      ( Date: 23-Feb-2022 18:33) Posted: COY BUY BACK 800,00 SHARES AT 1.21 & 1.22........hope to see ipo in china........

 

LONG TIS HOSPITAL AS A REFUGE......DEFENSIVE STOCK....

 

flw coy buy....attractive to long.....wat a jokes wth 3 hosp yet the px is still like donkey yrs ago....

halleluyah      ( Date: 23-Feb-2022 18:33) Posted: COY BUY BACK 800,00 SHARES AT 1.21 & 1.22........hope to see ipo in china........

 

COY BUY BACK 800,00 SHARES AT 1.21 & 1.22........hope to see ipo in china........

 

pls DYODD

annebelinda      ( Date: 23-Feb-2022 12:47) Posted: Company makes profit and still doomsday! You believe those monkeys?  ridethestorm      ( Date: 23-Feb-2022 11:49) Posted: haha, no one is worrying u worry? stock investment is about risk mgmt.... buy no scare, scare no buy

 

Company makes profit and still doomsday! You believe those monkeys? 

ridethestorm      ( Date: 23-Feb-2022 11:49) Posted: haha, no one is worrying u worry? stock investment is about risk mgmt.... buy no scare, scare no buy   annebelinda      ( Date: 23-Feb-2022 09:21) Posted: Worry too much also no point. Want to be a soldier must not be afraid of guns!

 

haha, no one is worrying
u worry?
stock investment is about risk mgmt....
buy no scare, scare no buy

 

annebelinda      ( Date: 23-Feb-2022 09:21) Posted: Worry too much also no point. Want to be a soldier must not be afraid of guns!

 

Long to enjoy. Prospects look good. Excited to see the share price climb when the China hospitals layer on earnings.

Financial Year	2015	2016	2017	2018	2019	2020	2021
Net Profit	69.0 million	67.9 million	68.7 million	67.7 million	58.2 million	64.7 million	83.7 million
Earnings Per Share (Diluted)	4.01 cents	4.00 cents	4.00 cents	3.97 cents	3.32 cents	3.58 cents	4.49 cents
Net Asset Value (Group)	34.96 cents	38.12 cents	41.45 cents	44.54 cents	46.00 cents	48.22 cents	51.43 cents
Share Price (1 day after annual report)	1.42 (Feb 2016)	1.46 (Feb 2017)	1.1 (Feb 2018)	1.12 (Feb 2019)	1.02 (Feb 2020)	1.02 (Feb 2021)	1.23 (Feb 2022)

 

Worry too much also no point. Want to be a soldier must not be afraid of guns! 

 

More covid test fr tis babe as record cases of 26,032.....lets cheong arh....

 

Don' t worry, Raffles Medical still got more business because those injured in war still need to heal. 

ridethestorm      ( Date: 22-Feb-2022 16:15) Posted: really un...un...unbelivable.. haha... after result out, jitao drop 6%, is like correction liao... still waiting for the shanghai hosp to break even in 3years time.. long ..... term...... pls dyodd   halleluyah      ( Date: 22-Feb-2022 14:56) Posted: hospital business is " pao" profitted wan............

 

really un...un...unbelivable.. haha...
after result out, jitao drop 6%, is like correction liao...
still waiting for the shanghai hosp to break even in 3years time..
long ..... term......
pls dyodd
 

halleluyah      ( Date: 22-Feb-2022 14:56) Posted: hospital business is " pao" profitted wan............. halleluyah      ( Date: 22-Feb-2022 14:51) Posted: long some old darling...............

 

hospital business is " pao" profitted wan.............

halleluyah      ( Date: 22-Feb-2022 14:51) Posted: long some old darling...............

 

buying on dips

 

long some old darling...............

 

wah, drop almost near to 5%...
if 1.24 support break, dunno how low it will go....
good to accumulate...
dyodd
 

ETLee8      ( Date: 22-Feb-2022 14:19) Posted: Profit of $44.7m is still very substantial and very good performance.  That is why it gives special dividend totalling 2.8cts. SG Gov is going to partner private hospitals such as Raffles Medical and GPs island wide (Raffles Medical has very substantial GP outlets in sg) to work on the new Healthcare for the people.  The budget is extremely substantial $19.3B.  Raffles Medical will be one of the major recepient of this new initiatives. BBs has pushed it low to reap maximum profits.  Suggest to accumulate more.  I expect there will be postive  write-outs of Raffles Medical once accumulation is completed. DYODD Joelton      ( Date: 22-Feb-2022 09:46) Posted: Raffles Medical posts 8.1% decline in H2 profit to S$44.7m RAFFLES Medical Group Raffles Medical: BSL -0.76% on Monday (Feb 21) announced that its net profit for the second half ended Dec 31, 2021 has dipped by 8.1 per cent to S$44.7 million, from S$48.6 million in the year-ago period.   This was attributed to higher tax expenses for H2 FY2021, as the period' s earnings before interest, taxes, depreciation and amortisation (Ebitda) had grown 4.9 per cent year on year to S$86.1 million from S$82.1 million, and H2 FY2020' s Ebitda had included S$9 million in Jobs Support Scheme grants received, which is not subject to tax.   Earnings per share for H2 FY2021 also declined by 9.1 per cent to S$0.0239, from S$0.0263 in H2 FY2020.   The board has recommended a final dividend of S$0.028 for FY2021, comprising a core dividend of S$0.018 and a special dividend of S$0.01, subject to shareholder approval at the next annual general meeting.   It had previously stated its intention to consolidate its interim and final dividends into an annual core dividend of up to half its average sustainable profit after tax and minority interests, starting in FY2021. An earlier guidance stated that the total FY2021 dividend would be " not less than S$0.025" .   Despite the drop in net profit, the private healthcare provider posted a H2 revenue jump of 16.3 per cent year on year to S$380 million, from S$326.8 million, due to the sale of Covid-19-related products and services.   It also noted that revenue for its healthcare services grew by 61.3 per cent in H2 FY2021, whereas its H2 FY2021 hospital services' top line went down by 6.2 per cent, both compared to the previous year. The group attributed this to Raffles Medical' s resources being deployed to support the various Covid-19 initiatives of the government, such as through the operation of vaccination centres and community testing.   Staff costs also dented earnings in the second half of last year, rising 31.7 per cent to S$204.1 million. Dr Loo Choon Yong, executive chairman of Raffles Medical Group, said that the company has 4,000 part-timers that it can supplement its workforce with when there are surges in demand due to Covid-19.   He also noted that productivity has gone down as the group deals with fluctuating Covid-19 demand, while regular patients avoid hospitals and clinics during the pandemic.   For the full-year FY2021, revenue went up 27.4 per cent year on year to S$723.8 million from S$568.2 million, which was matched by a 27.7 per cent year on year increase for net profit to S$84.2 million from S$65.9 million.   Looking forward, the group said it expects to remain profitable in FY2022 based on current circumstances and barring unforeseen circumstances, despite its Covid-19 support activities tapering off as the pandemic " evolves" .   Dr Loo said that demand for tests will remain for some time as more Singaporeans get tested to travel abroad. As more travellers enter Singapore, Raffles Medical Group will also continue administering tests to them at Changi Airport.   He also expects regional patients to return as international travel resumes, although demand remains uncertain.   &ldquo It&rsquo s a matter of pricing, it&rsquo s a matter of whether they now have renewed comfort, they&rsquo ve found local providers whom they&rsquo re comfortable with.   &ldquo I believe that Singapore will continue to be a hub because of quality and high standards so it may well be that total numbers may not be as great as before but the more seriously ill, the upper segment of the market will gravitate to Singapore,&rdquo he said.   Already, he noted that the government has, on a case-by-case basis, allowed foreign patients to enter for more serious medical operations like bone marrow transplants.   The group is also cautiously optimistic that its hospitals in China will continue to see improved patient loads.   Dr Loo said: " With Raffles Hospital Shanghai operational, we now have hospitals in 3 major cities in China. With this addition to our network of medical facilities and services in the region, we can serve even more local and international patients with our Raffles brand of quality healthcare services."   As for the group&rsquo s growth areas, Dr Loo noted that Finance Minister Lawrence Wong signalled in his Budget 2022 speech that partnerships between healthcare clusters and community partners should be improved, while preventive healthcare will also receive more attention.   &ldquo In my view as a healthcare expert, it makes sense that we can serve our ageing population more cost effectively&hellip the same item of care (in the community) is cheaper than in an acute hospital.   &ldquo Post-Covid, people are more interested in wellness, being healthy so that they will be strong against not just Covid-19, but other illnesses and I think that&rsquo s good,&rdquo he said.   In their research report on Feb 21, OCBC Investment Research analysts said that net profits, revenue and Ebitda were all above consensus expectations. It also maintained " buy" on the company with a fair value of S$1.65.   The analysts also said that the gradual regional re-opening of borders should be supportive of the group' s medium term recovery as foreign patients return.   " Overall, we see the incremental easing of travel restrictions, improving regional mobility and confidence to travel as supportive factors for Raffles&rsquo medium term earnings outlook," they said.   Additionally, the analysts noted that the group' s hospitals in China have continued to see improving traction, with management guiding for Raffles Chongqing to breakeven by the end of 2022 and Raffles Shanghai to see Ebitda breakeven 3 years from its commencement in the fourth quarter of 2021.   DBS analysts also noted that the company' s financial results were one of its best ever and exceeded their expectations as well. They maintained " buy" on the counter with a fair value of S$1.81.   Still, they noted that a key downside could be that hospital services revenue fell 6 per cent year-on-year in the second half of the year.

 

Profit of $44.7m is still very substantial and very good performance.  That is why it gives special dividend totalling 2.8cts.
SG Gov is going to partner private hospitals such as Raffles Medical and GPs island wide (Raffles Medical has very substantial GP outlets in sg) to work on the new Healthcare for the people.  The budget is extremely substantial $19.3B.  Raffles Medical will be one of the major recepient of this new initiatives.

BBs has pushed it low to reap maximum profits.  Suggest to accumulate more.  I expect there will be postive  write-outs of Raffles Medical once accumulation is completed.

DYODD

Joelton      ( Date: 22-Feb-2022 09:46) Posted: Raffles Medical posts 8.1% decline in H2 profit to S$44.7m RAFFLES Medical Group Raffles Medical: BSL -0.76% on Monday (Feb 21) announced that its net profit for the second half ended Dec 31, 2021 has dipped by 8.1 per cent to S$44.7 million, from S$48.6 million in the year-ago period.   This was attributed to higher tax expenses for H2 FY2021, as the period' s earnings before interest, taxes, depreciation and amortisation (Ebitda) had grown 4.9 per cent year on year to S$86.1 million from S$82.1 million, and H2 FY2020' s Ebitda had included S$9 million in Jobs Support Scheme grants received, which is not subject to tax.   Earnings per share for H2 FY2021 also declined by 9.1 per cent to S$0.0239, from S$0.0263 in H2 FY2020.   The board has recommended a final dividend of S$0.028 for FY2021, comprising a core dividend of S$0.018 and a special dividend of S$0.01, subject to shareholder approval at the next annual general meeting.   It had previously stated its intention to consolidate its interim and final dividends into an annual core dividend of up to half its average sustainable profit after tax and minority interests, starting in FY2021. An earlier guidance stated that the total FY2021 dividend would be " not less than S$0.025" .   Despite the drop in net profit, the private healthcare provider posted a H2 revenue jump of 16.3 per cent year on year to S$380 million, from S$326.8 million, due to the sale of Covid-19-related products and services.   It also noted that revenue for its healthcare services grew by 61.3 per cent in H2 FY2021, whereas its H2 FY2021 hospital services' top line went down by 6.2 per cent, both compared to the previous year. The group attributed this to Raffles Medical' s resources being deployed to support the various Covid-19 initiatives of the government, such as through the operation of vaccination centres and community testing.   Staff costs also dented earnings in the second half of last year, rising 31.7 per cent to S$204.1 million. Dr Loo Choon Yong, executive chairman of Raffles Medical Group, said that the company has 4,000 part-timers that it can supplement its workforce with when there are surges in demand due to Covid-19.   He also noted that productivity has gone down as the group deals with fluctuating Covid-19 demand, while regular patients avoid hospitals and clinics during the pandemic.   For the full-year FY2021, revenue went up 27.4 per cent year on year to S$723.8 million from S$568.2 million, which was matched by a 27.7 per cent year on year increase for net profit to S$84.2 million from S$65.9 million.   Looking forward, the group said it expects to remain profitable in FY2022 based on current circumstances and barring unforeseen circumstances, despite its Covid-19 support activities tapering off as the pandemic " evolves" .   Dr Loo said that demand for tests will remain for some time as more Singaporeans get tested to travel abroad. As more travellers enter Singapore, Raffles Medical Group will also continue administering tests to them at Changi Airport.   He also expects regional patients to return as international travel resumes, although demand remains uncertain.   &ldquo It&rsquo s a matter of pricing, it&rsquo s a matter of whether they now have renewed comfort, they&rsquo ve found local providers whom they&rsquo re comfortable with.   &ldquo I believe that Singapore will continue to be a hub because of quality and high standards so it may well be that total numbers may not be as great as before but the more seriously ill, the upper segment of the market will gravitate to Singapore,&rdquo he said.   Already, he noted that the government has, on a case-by-case basis, allowed foreign patients to enter for more serious medical operations like bone marrow transplants.   The group is also cautiously optimistic that its hospitals in China will continue to see improved patient loads.   Dr Loo said: " With Raffles Hospital Shanghai operational, we now have hospitals in 3 major cities in China. With this addition to our network of medical facilities and services in the region, we can serve even more local and international patients with our Raffles brand of quality healthcare services."   As for the group&rsquo s growth areas, Dr Loo noted that Finance Minister Lawrence Wong signalled in his Budget 2022 speech that partnerships between healthcare clusters and community partners should be improved, while preventive healthcare will also receive more attention.   &ldquo In my view as a healthcare expert, it makes sense that we can serve our ageing population more cost effectively&hellip the same item of care (in the community) is cheaper than in an acute hospital.   &ldquo Post-Covid, people are more interested in wellness, being healthy so that they will be strong against not just Covid-19, but other illnesses and I think that&rsquo s good,&rdquo he said.   In their research report on Feb 21, OCBC Investment Research analysts said that net profits, revenue and Ebitda were all above consensus expectations. It also maintained " buy" on the company with a fair value of S$1.65.   The analysts also said that the gradual regional re-opening of borders should be supportive of the group' s medium term recovery as foreign patients return.   " Overall, we see the incremental easing of travel restrictions, improving regional mobility and confidence to travel as supportive factors for Raffles&rsquo medium term earnings outlook," they said.   Additionally, the analysts noted that the group' s hospitals in China have continued to see improving traction, with management guiding for Raffles Chongqing to breakeven by the end of 2022 and Raffles Shanghai to see Ebitda breakeven 3 years from its commencement in the fourth quarter of 2021.   DBS analysts also noted that the company' s financial results were one of its best ever and exceeded their expectations as well. They maintained " buy" on the counter with a fair value of S$1.81.   Still, they noted that a key downside could be that hospital services revenue fell 6 per cent year-on-year in the second half of the year.